Dermira to Present at the 14th Annual Needham Healthcare Conference

MENLO PARK, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq: DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that it will present at the 14th Annual Needham Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 10:40 a.m. ET on Wednesday, April 15, 2015 in New York. A live audio webcast and replay of the presentation will be available in the Investors section of Dermira's corporate website at www.dermira.com.

About Dermira

Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Dermira's portfolio of five product candidates targets significant market opportunities and includes three late-stage product candidates: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe plaque psoriasis; DRM04, a topical treatment for hyperhidrosis; and DRM01, a topical sebum inhibitor for the treatment of acne. Dermira is headquartered in Menlo Park, California. For more information, please visit www.dermira.com.

CONTACT: Dermira Contact
         Andrew Guggenhime
         Chief Operating Officer and Chief Financial Officer
         650.421.7200
         [email protected]

         Investor Contact
         Westwicke Partners
         Robert H. Uhl
         Managing Director
         858.356.5932
         [email protected]

You May Also Be Interested In

• Needham Starts Red Violet (RDVT) at Buy, 'offers the leading Cloud identity intelligence platform in the market today'
• RDCY Partner Katherine A. Kiziah Appointed to Literacy Coalition of Palm Beach County Board of Directors
• Energy Vault’s 100 MW AI Infrastructure Project in Sardinia Receives Italian Government Designation as Project of Pre-Eminent National Strategic Interest